Skip to content
    INGN
    Earnings call· Jun 2026(Q2 FY26)

    Inogen Q2 FY26 earnings call INGN

    Aug 6, 2026 Source

    Executive summary

    Inogen Q2 FY26 — Revenue Miss, EBITDA Raise Amidst Channel Shift

    Inogen reported mixed Q2 FY26 results, with revenue falling short of prior guidance due to faster-than-anticipated channel shifts impacting US DTC and rental businesses, alongside international distributor inventory adjustments. Despite these top-line pressures, the company demonstrated strong international growth and improved profitability, leading to a raised full-year adjusted EBITDA outlook. Management is focused on leveraging new product traction, B2B channel expansion, and operational efficiencies to drive long-term growth and shareholder value.

    Highlights

    5

    • International revenue grew 15% year-over-year to $41.3 million, marking the 10th consecutive quarter of double-digit growth.

    • Adjusted EBITDA improved 15% year-over-year to $2.4 million, with full-year guidance raised to $4 million (48% growth over FY25).

    • Gross margin expanded by 65 basis points to 45.6% due to cost improvements and lower warranty expenses.

    • Generated $2.9 million in operating cash flow and $1 million in free cash flow, ending the quarter with $106.8 million in cash and no debt.

    • New products Voxy and Aurora contributed over 100 basis points to revenue growth, with Voxy shipping over 5,000 units and Aurora doubling customer count sequentially.

    Concerns

    5

    • Total revenue of $95.1 million grew only 3% year-over-year, missing previous expectations.

    • Full-year 2026 revenue guidance was lowered to $355 million-$361 million, a reduction from the prior range of $366 million-$373 million.

    • US sales decreased 2% year-over-year to $42.3 million, primarily due to continued pressure in the Direct-to-Consumer (DTC) channel.

    • US rentals declined 12% year-over-year to $11.6 million, reflecting structural sales channel mix shifts.

    • International distributor inventory management and timing of select purchases are expected to impact second-half revenue.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $355M-$361M
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    approximately $4M
    high materiality
    High
    Q3 2026 Reported Revenue
    in line with Q3 2025 reported revenue
    medium materiality
    High
    Long-term Revenue Growth
    high single-digit revenue growth
    high materiality
    Medium
    New Product Launch Frequency
    at least one new product launch per year
    medium materiality
    High
    US Sales Growth
    return to growth
    medium materiality
    Medium
    Aurora CPAP Mask Market Growth
    high single-digit rate
    low materiality
    High
    CEMIAC Market Growth
    high single digit rate
    low materiality
    High
    CEMIAC Regulatory Clearance (China)
    before the end of the year
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Total Revenue
    Primarily driven by strong international growth, favorable FX, and new product contributions.
    		$95.1M3%——
    US Sales
    Strong B2B growth was offset by channel mix challenges in DTC, where HMEs are increasingly prescribing POCs from day one. Expected to return to growth in H2 FY26.
    B2B sales channel growth: mid single-digitUS segment unit volume growth: high single digits
    		$42.3M-2%——
    International Sales
    Sustained mid-teen expansion across geographies and commercial initiatives, with penetration in existing countries and expansion into Eastern Europe and Latin America. Timing of select distributor purchases may impact H2.
    Consecutive quarters of double-digit growth: 10
    		$41.3M15%——
    US Rentals
    Reflects continued and structural sales channel mix shift, as more patients enter long-term oxygen therapy through HMEs with POCs, narrowing the traditional funnel for rental.
    		$11.6M-12%——

    Operational metrics

    20
    Adjusted Gross Margin
    45.6%up 65 bps YoY
    Q2 FY26

    Improved despite structural headwinds from channel mix shift.

    Adjusted Operating Expenses
    $44.6Mup 1.2% YoY
    Q2 FY26

    Overall increase in operating expenses.

    Adjusted R&D Expense
    $4.9Mup 13.3% YoY
    Q2 FY26

    Investment in clinical evidence generation and new product development.

    Adjusted SG&A Expense
    $39.8Min line with prior year
    Q2 FY26

    Investments for new products and B2B sales channel offset by cost reductions.

    GAAP Net Loss
    $3.9Mvs $4.2M net loss in prior year
    Q2 FY26

    Improved from prior year.

    Adjusted Net Loss
    <$0.1Mimproved nearly 95% YoY
    Q2 FY26

    Significant improvement from $0.7M adjusted net loss in prior year.

    Adjusted EBITDA
    $2.4Mup $0.3M YoY
    Q2 FY26

    Improved from $2.1M in prior year period.

    Cash, Cash Equivalents, Marketable Securities, and Restricted Cash
    $106.8M
    Q2 FY26 end

    Strong capital position with no debt outstanding.

    Share Repurchases
    $7.5M
    H1 FY26

    Reflects belief in undervalued stock and commitment to returning capital to shareholders.

    Total Revenue Foreign Exchange Impact
    240 bps
    Q2 FY26

    Favorable impact on total revenue.

    New Products Revenue Contribution
    over 100 bps
    Q2 FY26

    Contribution to total revenue growth.

    International Geo-expansion Contribution
    80 bps
    Q2 FY26

    Contribution to total revenue growth.

    Portable Oxygen Concentrator (POC) Unit Volume Growth
    over 12%YoY
    Q2 FY26

    Demonstrates outperformance of market growth.

    Voxy Units Shipped
    5,000+
    To date

    Positive early commercial performance for the stationary oxygen concentrator.

    Aurora CPAP Mask Customer Count Growth
    doubledsequentially
    Q2 FY26

    Strong early adoption for the new CPAP masks.

    Stationary Oxygen Concentrator (SOC) Market TAM (US)
    $300M
    Current

    Estimated Total Addressable Market for Voxy.

    CPAP Mask Market TAM (US)
    $2.2B
    Current

    Estimated Total Addressable Market for Aurora.

    CEMIAC Market TAM (US)
    $500M
    Current

    Estimated Total Addressable Market for CEMIAC.

    Total Combined TAM
    $3.4Bvs $400M 12 months ago
    Current

    Significantly expanded addressable market due to new product introductions.

    COPD Patients (Canada)
    2M
    Current

    Indicates large opportunity for Rhobe 6 launch.

    Industry KPIs

    5
    MetricValueDetails
    New product launch rampover 100 bpsbps
    Procedure volume growthover 12%%
    FCF conversion leverage guidance48%%
    Sales force commercial capacity buildincreased
    Indicated addressable patient population$300MUSD

    Product announcements

    1
    ProductTypeDetails
    Rhobe 6 Portable Oxygen Concentratorlaunch

    Risks & headwinds

    3
    US market channel mix shiftOngoing, expected to continue in H2 FY26

    US sales down 2% YoY; US rentals down 12% YoY

    Mitigation: Investing in B2B sales force, HME channel development, new product launches (Voxy, Aurora) to gain traction in B2B, evaluating options for rental business.

    International distributor inventory managementH2 FY26

    Impact on second half revenue

    Mitigation: Recognized as transitory, includes factors like delayed tenders and distributor consolidation. Confidence in long-term international growth trajectory.

    DTC sales channel pressureOngoing, expected to continue in H2 FY26

    Not enough to offset B2B growth in Q2

    Mitigation: Focus on B2B channel, new product sales through DTC, and overall US business growth to overcome headwinds.

    What to watch in Q3 FY26

    5

    Full-year Revenue Guidance

    next quarter
    Current$355M-$361M
    TargetReaffirmation or further revision

    Why it matters

    Revenue guidance was lowered this quarter, and its stability or further changes will indicate the effectiveness of mitigation strategies against channel shifts and international inventory dynamics.

    We are updating our full-year 2026 revenue guidance to a range of $355 million to $361 million, representing approximately 3% growth at the midpoint of the range. This represents a reduction from our previous guidance range of $366 million to $373 million.

    Q&A highlights

    6

    Is the DTC business a 'melting ice cube' with no bottom, or can new products like CPAP masks be sold through it to stabilize it?

    Management acknowledges the DTC channel is under pressure due to market shifts but believes it can stabilize and grow. They are evaluating options for the rental business and expect the total US business (B2B + DTC) to return to overall growth in the second half of the year. New products like Voxy are already sold through DTC, and opportunities exist for others.

    “But we do see opportunities when we look at the DTC for that's to stabilize and that to grow and we'll we're looking at the second half of this year, we're seeing that total US business and we bucket that together with the B2B US. We see as a being able to overcome that headwinds and see overall growth in the US business in the second half.”

    asked by Mike Madsen · answered by Unknown Speaker

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Focus and Market Dynamics

    Inogen is navigating a significant market shift where Home Medical Equipment (HME) providers are increasingly prescribing Portable Oxygen Concentrators (POCs) from day one, creating a tailwind for the B2B channel but pressure on the Direct-to-Consumer (DTC) and rental businesses. The company is actively managing its rental business with discipline and evaluating options to improve performance. Despite near-term headwind📎s, management expressed confidence in its strategy, aiming for high single-digit long-term revenue growth by expanding its presence in home respiratory care.

    02

    New Product Traction and Market Opportunity

    New products Voxy (stationary oxygen concentrator) and Aurora (CPAP masks) are gaining traction. Voxy has shipped over 5,000 units and addresses an estimated $300 million US Stationary Oxygen Concentrator (SOC) market. Aurora has more than doubled its customer count sequentially, targeting an estimated $2.2 billion US CPAP mask market growing at a high single-digit rate. These products are crucial for expanding Inogen's market reach and deepening relationships with B2B partners.

    03

    International Expansion Success

    International revenue grew 15% year-over-year to $41.3 million, marking the tenth consecutive quarter of double-digit growth. This expansion is sustained across geographies, with penetration in existing countries and further expansion into Eastern Europe and Latin America. Recent launches of the Rhobe 6 Portable Oxygen Concentrator in Canada and Brazil exemplify the deliberate international strategy to enter new geographies and extend patient access to high-quality portable oxygen therapy.

    04

    Profitability and Capital Allocation

    Adjusted EBITDA improved 15% year-over-year to $2.4 million, and the full-year adjusted EBITDA guidance was raised to $4 million, representing 48% growth over FY25. The company is conducting a thorough review of its P&L to align cost structure with growth priorities and ensure capital deployment drives growth and expands market value. Inogen generated $2.9 million in operating cash flow and ended the quarter with $106.8 million in cash with no debt, enabling continued investment in innovation and shareholder returns.

    05

    Clinical Pipeline and Scientific Credibility

    Inogen is advancing its clinical pipeline, including the CEMIAC (airway clearance) program. The IMPACT 200 trial enrollment for CEMIAC is progressing on track in the US, with the goal of securing CMS reimbursement for non-cystic fibrosis bronchiectasis, a $500 million TAM. In China, CEMIAC's SCOPE study completed enrollment, with statistical analysis results expected later this year. The company also published a manuscript in the ERS Open Resource Journal introducing the 'QUOTE' assessment tool, enhancing its scientific credibility in oxygen therapy.

    06

    Leadership and Operational Execution

    The company strengthened its leadership team with the addition of Andy Redding as Chief Operating Officer, a newly created role reflecting operational scale and executional demands. Mr. Redding brings over 30 years of med tech experience. This appointment, alongside increased focus on financial discipline and operational execution, is intended to drive improvement and long-term shareholder value amidst market dynamics.

    AI-generated summary of the company’s earnings call. Not investment advice.